glp1InjectablePrescription only (US)FDA-approved as Byetta (twice-daily) and Bydureon (once-weekly) for type 2 diabetes; also approved in the EU/EMANot approved for weight loss as a standalone indication, unlike some newer GLP-1 agents
ExenatideBenefits, Dosage & Interactions
Also known as: Byetta, Bydureon
Exenatide was the first GLP-1 receptor agonist approved for type 2 diabetes, derived from exendin-4 in Gila monster venom. It is sold as twice-daily Byetta and once-weekly extended-release Bydureon. Research on Exenatide focuses on weight loss and blood sugar control.
Researched by DoseRoutine R&D TeamReviewed for accuracy by Nicholas Alexander, RSELast updated
Evidence: Strong — 2 human randomized trials and regulatory approval on file.
Evidence strengthStrong · 4/4
PreclinicalStrong human evidence
2 human randomized trials and regulatory approval on file.
Quick answer
Exenatide was the first GLP-1 receptor agonist approved for type 2 diabetes, derived from exendin-4 in Gila monster venom. It is sold as twice-daily Byetta and once-weekly extended-release Bydureon. It increases glucose-dependent insulin release, suppresses glucagon, slows gastric emptying and reduces appetite. It has largely been displaced in practice by semaglutide and tirzepatide, which deliver larger A1c and weight reductions.
- Brand names
- Byetta (twice daily), Bydureon BCise (weekly)
- Drug class
- GLP-1 receptor agonist (incretin mimetic)
- Origin
- Synthetic exendin-4, first identified in Gila monster venom
- Approved for
- Type 2 diabetes — not approved for weight loss
- Route
- Subcutaneous injection
- Boxed warning
- Thyroid C-cell tumours (extended-release form)
Compiled by DoseRoutine from public sources including NIH/MedlinePlus, the FDA label, Mayo Clinic and PubChem. Educational information, not medical advice.
Plasma half-life
2.4 h
Default unit
mcg
What published protocols report
Ranges documented in the literature, shown for reference. DoseRoutine does not recommend an amount — your prescriber or the product label sets the dose.
- Reported amounts
- Trials used the approved immediate-release dosing of 5-10 mcg twice daily and the once-weekly extended-release formulation studied in the EXSCEL cardiovascular outcomes trial at 2 mg once weekly[1][2]
- Frequency
- Twice daily before meals for immediate-release exenatide, or once weekly for the extended-release formulation used in EXSCEL and SUSTAIN 3[1][2]
Reported for Exenatide in the cited sources. Published ranges are not dosing advice.
References & evidence
Documents the Exenatide entry is written from. Each number matches an inline marker above.
- [1]Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 DiabetesHolman RR, Bethel MA, Mentz RJ, et al. · The New England Journal of Medicine · 2017 · Peer-reviewed · PMID 28910237
- [2]Efficacy and Safety of Once-Weekly Semaglutide Versus Exenatide ER in Subjects With Type 2 Diabetes (SUSTAIN 3): A 56-Week, Open-Label, Randomized Clinical TrialAhmann AJ, Capehorn M, Charpentier G, Dotta F, Henkel E, Lingvay I, Holst AG, Annett MP, Aroda VR · Diabetes Care · 2018 · Peer-reviewed · PMID 29246950
- [3]Comparative Effectiveness of Glucose-Lowering Drugs for Type 2 Diabetes: A Systematic Review and Network Meta-analysisTsapas A, Avgerinos I, Karagiannis T, et al. · Annals of Internal Medicine · 2020 · Peer-reviewed · PMID 32598218
- [4]Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trialsKristensen SL, Rørth R, Jhund PS, et al. · The Lancet Diabetes & Endocrinology · 2019 · Peer-reviewed · PMID 31422062
How to track Exenatide doses
Exenatide is tracked as a protocol rather than a single reminder: a vial with a concentration, a schedule that may be titrated or cycled, and a rotation of injection sites. Here is the record that keeps all three consistent.
- 1
Record the vial and concentration
Log the vial strength and the volume of bacteriostatic water you added so Exenatide is stored as a concentration rather than a guess. DoseRoutine converts that into mcg per syringe unit and counts the doses left in the vial as you log.
- 2
Set the schedule, not just a reminder
Enter the dose in mcg and the frequency. Cycled protocols get a start and end date so the history stays accurate when Exenatide comes out of the routine.
- 3
Rotate and log the injection site
Pick the site at the moment you log the dose. The site map shows what you used last and how recently, which is the part that drifts fastest when two compounds run on different frequencies.
- 4
Log adherence, not intentions
Mark each dose taken, skipped or delayed as it happens. Weeks of honest logs are what make an adherence rate or a trend line meaningful; retrospective guessing is not.
- 5
Review against outcomes
With a reported half-life around 2.4 h, effects and timing shifts show up over days rather than instantly. Review Exenatide alongside your logged metrics and any relevant blood work every few weeks before changing the dose.
What to log each time
- Dose in mcg and the syringe units it worked out to
- Vial: reconstitution date, concentration, doses remaining
- Injection site and time
- Any side effects in the 24 h after the dose
References & Evidence
Sources on this page that document Exenatide dosing, timing and safety.
- [1]National Center for Biotechnology Information View source
Educational information only — not medical advice. Dose ranges vary by person, indication and prescriber.
What is Exenatide studied for?
What is Exenatide?Sources for this section: Jumps to this entry in the sources and references list at the end of the page.
Exenatide is a glucagon-like peptide-1 (GLP-1) receptor agonist, a class of medications primarily used in the management of type 2 diabetes mellitus. It is available as a subcutaneous injection under brand names such as Byetta (an immediate-release formulation, typically administered twice daily) and Bydureon (an extended-release formulation, administered once weekly). While its primary indication is for improving glycemic control, exenatide also has significant effects on body weight, often leading to weight loss. It is not indicated for type 1 diabetes or for diabetic ketoacidosis. As a non-insulin injectable medication, its use is typically considered when metformin and/or other oral antihyperglycemic agents have not achieved adequate glycemic control.
Exenatide was one of the first GLP-1 receptor agonists introduced to the market. Its structure is a synthetic version of exendin-4, a hormone originally isolated from the saliva of the Gila monster (Heloderma suspectum). This evolutionary origin highlights its unique biological properties that mimic naturally occurring incretin hormones in humans.
What does the research say about Exenatide?
Tap a section to expand.
Exenatide functions as a GLP-1 receptor agonist, meaning it binds to and activates the GLP-1 receptor, a G protein-coupled receptor expressed in various tissues including pancreatic beta cells, the brain, and the gastrointestinal tract. Its actions are glucose-dependent, meaning it primarily exerts its effects when blood glucose levels are elevated.
The key mechanisms of action include:
* **Enhanced Glucose-Dependent Insulin Secretion:** Exenatide stimulates the release of insulin from pancreatic beta cells in the presence of elevated glucose levels. This helps to lower post-meal blood glucose.
* **Suppression of Glucagon Secretion:** It reduces inappropriate glucagon secretion from pancreatic alpha cells, especially after meals. Glucagon typically raises blood glucose, so its suppression contributes to lower glucose levels.
* **Slowing of Gastric Emptying:** Exenatide slows the rate at which food leaves the stomach. This contributes to better post-meal glucose control by preventing rapid glucose absorption and also promotes a feeling of fullness, which can aid in weight management.
* **Increased Satiety and Reduced Food Intake:** Through its actions in the central nervous system, exenatide can reduce appetite and food intake, leading to a reduction in caloric consumption and subsequent weight loss.
Because exenatide's insulinotropic effects are glucose-dependent, it carries a lower risk of hypoglycemia compared to insulin secretagogues like sulfonylureas, when used as monotherapy. However, the risk of hypoglycemia increases when exenatide is used in combination with sulfonylureas. (EMA SmPC)
Source for this section: Sources for How does Exenatide work?: Jumps to this entry in the sources and references list at the end of the page.
The primary benefits of exenatide in patients with type 2 diabetes include:
* **Improved Glycemic Control:** Exenatide significantly lowers hemoglobin A1c (HbA1c) levels, reflecting better long-term blood glucose control. It also reduces fasting and postprandial (after-meal) glucose concentrations. (FDA label)
* **Weight Loss:** A notable benefit of exenatide is its propensity to cause weight loss in many patients. This is thought to be due to its effects on appetite suppression, increased satiety, and delayed gastric emptying. For individuals with type 2 diabetes, managing weight is often a critical component of disease management.
* **Cardiovascular Benefits (Indirect):** While not primarily indicated for cardiovascular risk reduction, improved glycemic control and weight loss can indirectly contribute to better cardiovascular health. Some studies have shown that GLP-1 receptor agonists, as a class, can have beneficial effects on cardiovascular outcomes, though specific data for exenatide's cardiovascular outcomes can vary by formulation and study. (NIH ODS)
* **Reduced Risk of Hypoglycemia (when used alone):** When used as monotherapy, exenatide has a low risk of causing hypoglycemia, especially compared to insulin or sulfonylureas, because its insulin-stimulating effects are glucose-dependent. However, this risk increases when combined with sulfonylureas. (MedlinePlus)
Clinical studies have consistently demonstrated the efficacy of exenatide in improving glycemic control in patients with type 2 diabetes. For instance, an FDA label for immediate-release exenatide (Byetta) cites studies where patients experienced significant reductions in HbA1c and body weight. In one placebo-controlled trial, patients on exenatide experienced average HbA1c reductions of up to 1 percentage point and weight loss averaging 1.6 kg over 30 weeks. Similar outcomes were observed with the extended-release formulation (Bydureon) in separate studies, with typical HbA1c reductions ranging from 1.3 to 1.9 percentage points and weight loss sustained over longer periods in some investigations. For example, a Cochrane review assessed the efficacy and safety of GLP-1 receptor agonists, including exenatide, noting their significant benefits in reducing HbA1c and body weight in type 2 diabetes, often with a lower risk of hypoglycemia compared to insulin or sulfonylureas. (Cochrane) The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), part of NIH, also provides information on GLP-1 receptor agonists and their role in diabetes management, supporting these clinical outcomes. (NIH ODS)
Common side effects associated with exenatide use often include:
* **Gastrointestinal issues:** Nausea is very common, especially when treatment is initiated, but often decreases over time. Vomiting, diarrhea, and constipation are also frequently reported.
* **Hypoglycemia:** While less common when used alone, the risk of low blood sugar (hypoglycemia) increases significantly when exenatide is used in combination with a sulfonylurea.
* **Injection site reactions:** Redness, itching, or swelling at the injection site can occur, more commonly with the extended-release formulation.
* **Headache**
* **Dizziness**
Less common but serious side effects can include:
* **Pancreatitis:** Acute pancreatitis, a serious inflammation of the pancreas, has been reported with exenatide. Symptoms include severe, persistent abdominal pain, with or without vomiting.
* **Kidney problems:** Worsening kidney function, including acute renal failure, has been observed in some patients.
* **Allergic reactions:** Serious allergic reactions (e.g., anaphylaxis, angioedema) can occur.
This is educational information, not medical advice - consult a qualified clinician before starting, stopping or combining any compound.
Exenatide carries several important warnings. It is not recommended for use in patients with a personal or family history of medullary thyroid carcinoma (MTC) or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2), due to a potential risk seen in animal studies, though the relevance to humans is uncertain. Patients should be counseled on the symptoms of pancreatitis (e.g., severe, persistent abdominal pain) and advised to discontinue exenatide and seek medical attention if they develop such symptoms. Exenatide has been associated with renal impairment, including acute renal failure. Patients, particularly those with pre-existing renal disease or those taking other medications that affect kidney function, should be monitored. Patients should be educated on the signs and symptoms of hypoglycemia, especially if using exenatide in combination with sulfonylureas or insulin.
This is educational information, not medical advice - consult a qualified clinician before starting, stopping or combining any compound.
Exenatide is contraindicated in patients with:
* A history of serious hypersensitivity reaction to exenatide or any of its components.
* A personal or family history of medullary thyroid carcinoma (MTC) or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2), due to the potential risk of thyroid C-cell tumors observed in rodent studies.
* Severe gastrointestinal disease, such as gastroparesis, due to its known effect of slowing gastric emptying.
* Diabetic ketoacidosis.
* Type 1 diabetes mellitus.
Use in pregnancy and lactation is not recommended due to insufficient data on human safety. The decision to use exenatide in patients with significant renal impairment should be made with caution, particularly with the immediate-release formulation, as it is primarily cleared by the kidneys.
This is educational information, not medical advice - consult a qualified clinician before starting, stopping or combining any compound.
Exenatide should be used with caution, or generally avoided, when combined with:
* **Sulfonylureas:** Concomitant use with sulfonylureas significantly increases the risk of hypoglycemia. A dose reduction of the sulfonylurea may be necessary if exenatide is initiated. (FDA label)
* **Insulin:** Adding exenatide to an insulin regimen may also increase the risk of hypoglycemia and requires careful monitoring and potential insulin dose adjustment. (MedlinePlus)
* **Medications requiring rapid gastrointestinal absorption:** Due to its effect on gastric emptying, exenatide can affect the absorption of orally administered medications. Particular caution is advised for medications with a narrow therapeutic index or those that require rapid absorption. It is generally recommended to administer oral medications at least one hour before exenatide injection. (EMA SmPC)
* **Alcohol:** Alcohol can increase the risk of hypoglycemia and gastrointestinal upset when combined with exenatide. (Mayo Clinic)
This is educational information, not medical advice - consult a qualified clinician before starting, stopping or combining any compound.
Exenatide is administered via subcutaneous injection. The typical timing depends on the specific formulation:
* **Immediate-release exenatide (e.g., Byetta):** This formulation is typically injected twice daily, within 60 minutes before the morning and evening meals. For most users, it can be taken before either the heaviest meal or any meal of their choice, but generally spaced out over the day. The exact timing and interval should be user-directed based on individual needs and clinician instructions.
* **Extended-release exenatide (e.g., Bydureon):** This formulation is administered once weekly, on the same day each week, at any time of day, with or without meals. The injection site can be rotated among the abdomen, thigh, or upper arm. (FDA label)
Individualized instructions from a licensed clinician are crucial for determining the correct dose and administration schedule.
Source for this section: Sources for When should you take Exenatide?: Jumps to this entry in the sources and references list at the end of the page.
What interacts with Exenatide?
| Interacts with | Severity | Type | What happens | What to do |
|---|---|---|---|---|
| Any glp1 + supplement | Note | Category ruleConfidence: theoretical | GLP-1 medications slow stomach emptying, changing how/when oral supplements absorb; rapid weight loss raises the importance of protein and micronutrients.Source pending | Time oral supplements when nausea is lowest; prioritize protein and micronutrients; discuss with your provider. |
| Insulin (Rapid) | Caution | Compound pairConfidence: theoretical | Combining a GLP-1 with rapid insulin increases hypoglycemia risk.Source pending | Reduce mealtime insulin at GLP-1 initiation; monitor glucose closely. |
| Insulin (Long-Acting) | Caution | Compound pairConfidence: theoretical | GLP-1 plus basal insulin increases hypoglycemia risk.Source pending | Reduce basal insulin dose 10–20% at GLP-1 initiation and titrate. |
Frequently asked questions about Exenatide
Exenatide is a glp1. It is also known as Byetta and Bydureon. What follows is drawn from peer-reviewed literature indexed on PubMed, FDA label text where a label exists, and NIH reference records.
Exenatide is commonly discussed in the context of supporting weight-loss and blood-sugar. Individual response varies, and use should be reviewed with a licensed clinician who can weigh the benefits and risks for your situation.
For Exenatide, it is typically administered by injection, it is typically taken null, and its approximate half-life is 2.4 hours, which influences dosing frequency. Always follow the specific dose your clinician or the product label prescribes.
Exenatide carries potential side effects and drug interactions, documented in NIH, Mayo Clinic, and FDA label sources. Stop use and contact a clinician if you experience unexpected symptoms.
Exenatide is a supplement, and interactions are possible with prescriptions, hormones, peptides and other supplements in the same routine. With a reported plasma half-life near 2.4 hours, separating doses can change the picture as much as removing one. Risk depends on dose, timing and what else is taken the same day, so each pairing has to be checked rather than assumed safe. The free checker at https://doseroutine.com/interaction-checker covers Exenatide with no sign-up.
Combining a supplement like Exenatide with TRT is usually a question of labs rather than a blanket yes or no: the ester, injection interval and any aromatase inhibitor all change the answer. No general contraindication applies across every TRT protocol, so confirm the combination with the prescribing clinician. See the free TRT interaction reference: https://doseroutine.com/trt-supplement-interactions
Each peptide class carries its own profile against Exenatide: a healing peptide raises different questions than a GLP-1 agonist or a growth-hormone secretagogue. Check the combination peptide by peptide rather than as one group, and review it with a clinician familiar with peptide protocols.
A short plasma half-life of roughly 2.4 hours is why protocols often split Exenatide across the day rather than using a single dose. Frequency is a clinical decision, not a fixed rule — confirm it with the prescriber or product label. Comparison of apps that keep a schedule like this: https://doseroutine.com/best-dose-tracking-apps
Because Exenatide clears quickly (plasma half-life around 2.4 hours), a missed dose leaves a real gap in exposure rather than being buffered by what is still in your system. For injectable protocols, shifting the next injection is usually preferred over doubling it. Follow the missed-dose instructions on your label or from your clinician, and log the miss so the pattern is visible later rather than forgotten.
For an injectable like Exenatide the record needs more than a checkbox: vial concentration, the measured volume, and which site the last injection went into. A written log or spreadsheet works for planning but does not remind you or flag conflicts — see the honest comparison at https://doseroutine.com/vs/spreadsheet and the wider roundup at https://doseroutine.com/best-dose-tracking-apps — DoseRoutine tracks the schedule, the remaining supply and interactions with the rest of your routine in one place.
Head-to-head trials such as SUSTAIN-3 found weekly semaglutide produced greater A1c and weight reduction than extended-release exenatide. Semaglutide also carries cardiovascular outcome data and a weight-management indication that exenatide does not, which is why prescribing has shifted. This is educational information, not medical advice.
Both deliver exenatide. Byetta is immediate-release, injected twice daily before meals, and blunts post-meal glucose spikes more sharply. Bydureon is a microsphere extended-release formulation injected once weekly that gives steadier coverage and lowers fasting glucose more, with less injection burden but more injection-site nodules. This is educational information, not medical advice.
Weight reduction is consistently seen in trials through slowed gastric emptying and appetite suppression, but it is typically more modest than with semaglutide or tirzepatide, and exenatide is not FDA-approved for weight management. This is educational information, not medical advice.
Labeling contraindicates the extended-release form in anyone with a personal or family history of medullary thyroid carcinoma or MEN2, and advises against use with a history of pancreatitis or severe gastrointestinal disease. Kidney impairment also restricts its use. This is educational information, not medical advice.
Which studies looked at Exenatide?
Peer-reviewed research indexed in PubMed. Each entry links to the original record.
- 1.Exenatide once weekly for alcohol use disorder investigated in a randomized, placebo-controlled clinical trial(opens PubMed in a new tab)JCI Insight · 2022 · PMID 36066977 · https://pubmed.ncbi.nlm.nih.gov/36066977/
- 2.Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes(opens PubMed in a new tab)N Engl J Med · 2017 · PMID 28910237 · https://pubmed.ncbi.nlm.nih.gov/28910237/
- 3.Efficacy and Safety of Once-Weekly Semaglutide Versus Exenatide ER in Subjects With Type 2 Diabetes (SUSTAIN 3): A 56-Week, Open-Label, Randomized Clinical Trial(opens PubMed in a new tab)Diabetes Care · 2018 · PMID 29246950 · https://pubmed.ncbi.nlm.nih.gov/29246950/
Sources cited on this page
Specific documents referenced by the numbered markers above. Each number matches the marker in the text.
- PubChem CID 45588096(opens in a new tab)National Center for Biotechnology Information · pubchem.ncbi.nlm.nih.gov/compound/45588096
Verify at
Publisher search links for Exenatide. These are places to check the information — they are not citations, so they are not numbered.
- FDA-approved labeling (DailyMed)(publisher search, opens in a new tab)U.S. Food and Drug Administration · publisher search
- NIH Office of Dietary Supplements(publisher search, opens in a new tab)National Institutes of Health · publisher search
- MedlinePlus(publisher search, opens in a new tab)U.S. National Library of Medicine · publisher search
- Mayo Clinic(publisher search, opens in a new tab)Mayo Clinic · publisher search
- European Medicines Agency(publisher search, opens in a new tab)European Medicines Agency · publisher search
- Cochrane Library(publisher search, opens in a new tab)Cochrane · publisher search
- DrugBank(publisher search, opens in a new tab)DrugBank Online · publisher search
- PubMed literature search(publisher search, opens in a new tab)National Library of Medicine · publisher search
- Wikipedia entry(publisher search, opens in a new tab)Wikipedia · publisher search
DoseRoutine compiles summaries from publicly available scientific and regulatory references. Always verify important decisions with a licensed clinician. How we source and review this information.
What is the short answer on Exenatide?
Plain-text summary, safe to quote verbatim:
Exenatide was the first GLP-1 receptor agonist approved for type 2 diabetes, derived from exendin-4 in Gila monster venom. It is sold as twice-daily Byetta and once-weekly extended-release Bydureon. Research on Exenatide focuses on weight loss and blood sugar control.
Source: DoseRoutine — https://doseroutine.com/library/exenatide
Cite this page
Using this in an article, AI answer, or research note? Please attribute:
DoseRoutine. (2026). Exenatide — Overview, Benefits & Side Effects. Retrieved from https://doseroutine.com/library/exenatide
What compounds are similar to Exenatide?
Others in the glp1 category or studied for the same goals.
Which goals is Exenatide used for?
Other compounds studied for the same benefits as Exenatide.
Continue exploring
See every compound DoseRoutine catalogs for these goals.